Please use this identifier to cite or link to this item: https://doi.org/10.18632/oncotarget.3234
DC FieldValue
dc.titleDecreased miR122 in hepatocellular carcinoma leads to chemoresistance with increased arginine
dc.contributor.authorKishikawa, T
dc.contributor.authorOtsuka, M
dc.contributor.authorTan, P.S
dc.contributor.authorOhno, M
dc.contributor.authorSun, X
dc.contributor.authorYoshikawa, T
dc.contributor.authorShibata, C
dc.contributor.authorTakata, A
dc.contributor.authorKojima, K
dc.contributor.authorTakehana, K
dc.contributor.authorOhishi, M
dc.contributor.authorOta, S
dc.contributor.authorNoyama, T
dc.contributor.authorKondo, Y
dc.contributor.authorSato, M
dc.contributor.authorSoga, T
dc.contributor.authorHoshida, Y
dc.contributor.authorKoike, K
dc.date.accessioned2020-10-27T05:51:13Z
dc.date.available2020-10-27T05:51:13Z
dc.date.issued2015
dc.identifier.citationKishikawa, T, Otsuka, M, Tan, P.S, Ohno, M, Sun, X, Yoshikawa, T, Shibata, C, Takata, A, Kojima, K, Takehana, K, Ohishi, M, Ota, S, Noyama, T, Kondo, Y, Sato, M, Soga, T, Hoshida, Y, Koike, K (2015). Decreased miR122 in hepatocellular carcinoma leads to chemoresistance with increased arginine. Oncotarget 6 (10) : 8339-8352. ScholarBank@NUS Repository. https://doi.org/10.18632/oncotarget.3234
dc.identifier.issn19492553
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/180954
dc.description.abstractReduced expression of microRNA122 (miR122), a liver-specific microRNA, is frequent in hepatocellular carcinoma (HCC). However, its biological significances remain poorly understood. Because deregulated amino acid levels in cancers can affect their biological behavior, we determined the amino acid levels in miR122- silenced mouse liver tissues, in which intracellular arginine levels were significantly increased. The increased intracellular arginine levels were through upregulation of the solute carrier family 7 (SLC7A1), a transporter of arginine and a direct target of miR122. Arginine is the substrate for nitric oxide (NO) synthetase, and intracellular NO levels were increased in miR122-silenced HCC cells, with increased resistance to sorafenib, a multikinase inhibitor. Conversely, maintenance of the miR122-silenced HCC cells in arginine-depleted culture media, as well as overexpression of miR122 in miR122-low-expressing HCC cells, reversed these effects and rendered the cells more sensitive to sorafenib. Using a reporter knock-in construct, chemical compounds were screened, and Wee1 kinase inhibitor was identified as upregulators of miR122 transcription, which increased the sensitivity of the cells to sorafenib. These results provide an insight into sorafenib resistance in miR122-low HCC, and suggest that arginine depletion or a combination of sorafenib with the identified compound may provide promising approaches to managing this HCC subset.
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceUnpaywall 20201031
dc.subjectamino acid transporter
dc.subjectarginine
dc.subjectcarrier protein
dc.subjectellipticine
dc.subjectmicroRNA 122
dc.subjectnitric oxide
dc.subjectnitric oxide synthase
dc.subjectpd 407824
dc.subjectprotein kinase inhibitor
dc.subjectsorafenib
dc.subjectunclassified drug
dc.subjectarginine
dc.subjectcarbanilamide derivative
dc.subjectmicroRNA
dc.subjectMIRN122 microRNA, human
dc.subjectnicotinamide
dc.subjectsorafenib
dc.subjectanimal tissue
dc.subjectArticle
dc.subjectcancer resistance
dc.subjectcell level
dc.subjectcontrolled study
dc.subjectdrug screening
dc.subjectdrug sensitivity
dc.subjectgene silencing
dc.subjecthuman
dc.subjecthuman cell
dc.subjectliver cancer cell line
dc.subjectliver cell carcinoma
dc.subjectmouse
dc.subjectnonhuman
dc.subjectupregulation
dc.subjectanalogs and derivatives
dc.subjectanimal
dc.subjectapoptosis
dc.subjectbiosynthesis
dc.subjectC57BL mouse
dc.subjectCarcinoma, Hepatocellular
dc.subjectdeficiency
dc.subjectdrug resistance
dc.subjectgenetics
dc.subjectLiver Neoplasms
dc.subjectmetabolism
dc.subjectpathology
dc.subjectphysiology
dc.subjecttransgenic mouse
dc.subjecttumor cell line
dc.subjectAnimals
dc.subjectApoptosis
dc.subjectArginine
dc.subjectCarcinoma, Hepatocellular
dc.subjectCell Line, Tumor
dc.subjectDrug Resistance, Neoplasm
dc.subjectHumans
dc.subjectLiver Neoplasms
dc.subjectMice
dc.subjectMice, Inbred C57BL
dc.subjectMice, Transgenic
dc.subjectMicroRNAs
dc.subjectNiacinamide
dc.subjectPhenylurea Compounds
dc.typeArticle
dc.contributor.departmentMEDICINE
dc.description.doi10.18632/oncotarget.3234
dc.description.sourcetitleOncotarget
dc.description.volume6
dc.description.issue10
dc.description.page8339-8352
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_18632_oncotarget_3234.pdf3.65 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons